Breaking News

Scantox Group Acquires UK-based CRO Gentronix

The deal gives Gentronix access to new global opportunities while enabling Scantox to expand its services in response to client demands.

Author Image

By: Charlie Sternberg

Associate Editor

Gentronix, a UK-based contract research organization (CRO) specializing in genetic toxicology, has been acquired by Scantox Group of Denmark for an undisclosed sum.   The deal provides an exit for Mercia Ventures’ Northern Venture Capital Trusts (VCTs), which have sold their stake in the business for £14.8 million ($19.4m), representing a 4.5x return on investment.   Gentronix, which is based in Alderley Park in Cheshire, provides predictive toxicology services to the global pharma and chemi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters